Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01197495 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation
A NA study, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 213
- Enrollment target
NCT01197495: Completed NA study, sponsored by Allergan.
NCT01197495 is a NA study that has completed, run by Allergan. The registered enrollment target is 213 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01197495, a NA study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 213 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and effectiveness of Juvederm(R) Ultra XC Injectable Gel for lip augmentation
Primary Outcome
Overall lip fullness is assessed by the blinded Evaluating Investigator compared to baseline using the 5-point LFS2. Scores range from 1=minimal improvement to 5=very marked improvement.
Interventions
- DEVICE hyaluronic acid gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2010-08-01 |
| Est. Completion | 2015-06-15 |
| Phase | NA |
What the finished NCT01197495 record still lists
NCT01197495 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which hyaluronic acid gel is the first listed.
NCT01197495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01197495 about?
NCT01197495 is a clinical study titled "Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation". The purpose of this study is to demonstrate the safety and effectiveness of Juvederm(R) Ultra XC Injectable Gel for lip augmentation
What is the current status of trial NCT01197495?
This trial is currently completed. It is a NA study. The enrollment target is 213 participants. The study started on 2010-08-01. Estimated completion is 2015-06-15.
What interventions are being tested in trial NCT01197495?
The interventions under investigation include: hyaluronic acid gel (DEVICE).
Who is sponsoring clinical trial NCT01197495?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01197495's enrollment target sits among peer trials
213 488th of 2000 higher than 1,512 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI